knowledge -WSS

knowledge

author：knowledge 2025-09-29 01:34:45 - browse：5876

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Lawmakers consider Medicare pay reforms for doctors

WSS

Excited delirium, Elijah McClain, and emergency physicians

First Opinion Podcast: Long Covid needs a new approach

Researchers explore possible ties between long Covid, menopause

The explosion of genetic testing requires a new approach

First Opinion Podcast: Long Covid needs a new approach

White House calls on federal agencies to crack down on AI abuses

explore

knowledge

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare will require more price transparency from hospitals

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare reduced heart disease by changing how it pays doctors

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CEOs share strategies for surviving biotech slump

Activists slam private health insurers over coverage restrictions

Impact of Dobbs ruling felt at reproductive medicine meeting

What does generative AI mean for health care? We asked experts

STAT Summit: How a Chicago ER doctor tackles gun violence

leisure time

Studies point to risks of excluding people with obesity from drug trials

A clever new way to fix Medicaid and graduate medical education

UnitedHealth’s board chair also owns a personal investment firm

First Opinion Podcast: Long Covid needs a new approach

STAT Summit: Michael J. Fox on progress in Parkinson's research

Excited delirium, Elijah McClain, and emergency physicians

Wikipedia

focus

knowledge

Wikipedia